Methylene blue
- Generic Name
- Methylene blue
- Brand Names
- Hyophen, Phosphasal, Provayblue, Proveblue, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Urogesic Blue Reformulated Apr 2012, Ustell, Utira, Lumeblue (previously known as Methylthioninium chloride Cosmo), Methylthioninium chloride Proveblue
- Drug Type
- Small Molecule
- Chemical Formula
- C16H18ClN3S
- CAS Number
- 61-73-4
- Unique Ingredient Identifier
- 8NAP7826UB
- Background
Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinar...
- Indication
Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
...
- Associated Conditions
- Cystitis, Methemoglobinemia, Nephritis, Urethritis, Urinary tract inflammation
- Associated Therapies
- Diuresis
FDA Approves Methylene Blue Injection for Acquired Methemoglobinemia
Methylene Blue Injection, USP (Nexus Pharmaceutical, LLC) received FDA approval for treating acquired methemoglobinemia (MetHb). This condition, characterized by abnormal methemoglobin production, can be inherited or acquired through medication exposure. Methylene Blue reduces oxidized hemoglobin (Fe3+) to its functional form (Fe2+), enhancing oxygen-binding capacity. The approval expands treatment options for MetHb, improving patient outcomes.
Dialogue with the founder of Pump.Science: When will the next DeSci+meme experiment ...
Benjels, co-founder of pump.science, discusses DeSci innovation, tokenizing drug IP, and plans to launch 20 new experimental tokens around Christmas, emphasizing the potential of DeSci to fund medical research and longevity technologies.
Latest interview with the founder of Pump.Science: After RIF and URO, what is the next ...
Benjels, co-founder of pump.science, discusses DeSci innovations, focusing on raising experimental funds through token trading for medical and longevity technologies. He reveals pump.science will launch nearly 20 new experimental tokens around Christmas, tokenizing drug compounds' intellectual property for investment. The project aims to gamify science, attract investors with experimental data, and eventually scale up to human testing and product market development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath